This has been further reflected in the involvement of CAMKK2 in several metabolic diseases characterized by the manifestation of dysregulated mitochondrial function as part of their pathogenic process, including, for example, cancer [84, 90–92], obesity [83], diabetes [54], neurodegeneration [16, 17], and NAFLD [76]. This evidence concerns the gene CAMKK2 and diabetes mellitus.